❮ Back to Researchers

Shelley Boyd

MD, FRCS(C), DABO, BSc

Investigator

Email: Shelley.Boyd@unityhealth.to
Tel: 416-864-3138

Biography

Dr. Shelley Boyd is an ophthalmologist & clinician-scientist focused on “dry” Age Related Macular Degeneration (AMD). She is an Assistant Professor with the University of Toronto in the Department of Ophthalmology & Vision Sciences (DOVS) and Laboratory Medicine & Pathobiology (LMP) and is cross-appointed to Biomedical Engineering at McMaster University. She is the founding director of Canada’s only dedicated “High Risk Dry AMD Clinic”, a clinical research facility at St. Michael’s Hospital, where she uses specialized imaging and a patient-centered registry to understand and compare the different subtypes of dry AMD. Working within the Keenan Research Centre of Biomedical Science at St. Michael’s Hospital, her lab focuses on finding new therapies for this blinding disease. Dry AMD effects 85% of patients with late disease and no treatments exist.

Dr. Boyd was previously Head of the Ocular Angiogenesis research program, world-wide, for Novartis pharmaceuticals (Basel, Switzerland) where she led the pre-clinical and translational aspects of the Lucentis program, the standard-of-care treatment for “wet” AMD. Working with St. Michael’s Hospital – and with the goal of turning science into medicine – she recently founded a biotech company, Translatum Medicus inc (TMi), that uniquely combines her background in science, medicine and the pharmaceutical industry with the hospital’s mission to be leaders in knowledge translation. Dr. Boyd is President and Chief Scientific Officer of TMi.

Recent Publications

  1. Alsarhani, WK, Chan, CC, Boyd, SR, Hasso, M, Almeer, A, Tan, DHS et al.. Monkeypox-Associated Disciform Keratitis. Cornea. 2023;42 (5):641-644. doi: 10.1097/ICO.0000000000003171. PubMed PMID:36729600 PubMed Central PMC10060039.
  2. Pankova, N, Baek, DSH, Zhao, X, Wang, H, Reyad, MM, Liang, H et al.. Evolving Patterns of Hyperfluorescent Fundus Autofluorescence Accompany Retinal Atrophy in the Rat and Mimic Atrophic Age-Related Macular Degeneration. Transl Vis Sci Technol. 2022;11 (3):3. doi: 10.1167/tvst.11.3.3. PubMed PMID:35254423 PubMed Central PMC8914569.
  3. Felfeli, T, Juncal, VR, Hillier, RJ, Mak, MYK, Wong, DT, Berger, AR et al.. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema. Am J Ophthalmol. 2019;206 :176-183. doi: 10.1016/j.ajo.2019.04.002. PubMed PMID:30959004 .
  4. Hillier, RJ, Ojaimi, E, Wong, DT, Mak, MYK, Berger, AR, Kohly, RP et al.. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. JAMA Ophthalmol. 2018;136 (4):382-388. doi: 10.1001/jamaophthalmol.2018.0179. PubMed PMID:29522144 PubMed Central PMC5876836.
  5. Liu, S, Dozois, MD, Chang, CN, Ahmad, A, Ng, DL, Hileeto, D et al.. Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage. Mol Pharm. 2016;13 (9):2897-905. doi: 10.1021/acs.molpharmaceut.6b00445. PubMed PMID:27482595 .
  6. Hillier, RJ, Ojaimi, E, Wong, DT, Mak, MY, Berger, AR, Kohly, RP et al.. AQUEOUS HUMOR CYTOKINE LEVELS AS BIOMARKERS OF DISEASE SEVERITY IN DIABETIC MACULAR EDEMA. Retina. 2017;37 (4):761-769. doi: 10.1097/IAE.0000000000001210. PubMed PMID:27471825 .
  7. Joshi, R, Pankova, N, Wang, H, Baek, DS, Zhao, X, Reyad, M et al.. Spontaneously occurring fundus findings observed using confocal scanning laser ophthalmoscopy in wild type Sprague Dawley rats. Regul Toxicol Pharmacol. 2016;77 :160-6. doi: 10.1016/j.yrtph.2016.02.002. PubMed PMID:26873774 .
  8. Torisu, K, Singh, KK, Torisu, T, Lovren, F, Liu, J, Pan, Y et al.. Intact endothelial autophagy is required to maintain vascular lipid homeostasis. Aging Cell. 2016;15 (1):187-91. doi: 10.1111/acel.12423. PubMed PMID:26780888 PubMed Central PMC4717267.
  9. Navajas, EV, Krema, H, Hammoudi, DS, Lipton, JH, Simpson, ER, Boyd, S et al.. Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Can J Ophthalmol. 2015;50 (6):442-50. doi: 10.1016/j.jcjo.2015.08.003. PubMed PMID:26651304 .
  10. Sheikholeslami, P, Muirhead, B, Baek, DS, Wang, H, Zhao, X, Sivakumaran, D et al.. Hydrophobically-modified poly(vinyl pyrrolidone) as a physically-associative, shear-responsive ophthalmic hydrogel. Exp Eye Res. 2015;137 :18-31. doi: 10.1016/j.exer.2015.05.021. PubMed PMID:26044117 .
Search PubMed

Affiliations & Other Activities

  • Clinician-Scientist, Ophthalmology, St. Michael’s Hospital
  • Founding Director, Visual Electrophysiology Unit, Ophthalmology, St. Michael’s Hospital
  • Assistant Professor, Ophthalmology and Vision Sciences, University of Toronto
  • Director, Peter and Louise Walter Retinal Regeneration Laboratory, Vascular Biology
  • Adjunct Assistant Professor, School of Biomedical Engineering, McMaster University